2020-11-13T11:05:08-06:00 2019-12-31 454060696 CCA LLP 2300 Contra Costa Blvd Pleasant Hill CA 94523 990 2019-01-01 943473864 Sens Foundation Inc SENS 6503361780 110 Pioneer Way No J Mountain View CA 94041 James O'Neill CEO 6503361780 2020-11-13 1 CCA LLP P00587987 9256852911 2020-11-13 99.24.132.41 2020-11-13 11:05:04 PS P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 D8FC6D2B4B961B03C3571F252B9F796928178899 2019 2021-01-29 14:40:06Z Sens Research Foundation Inc James O'Neill 110 Pioneer Way No J Mountain View CA 94041 3275052 0 X WWW.SENS.ORG X 2009 CA Develop, promote and ensure widespread access to rejuvenation biotechnologies. 9 8 34 9 27600 9124 3531916 2589086 0 0 -1105802 -32234 10459 99398 2436573 2656250 720223 634386 0 0 1542445 2239046 0 0 332467 1305591 1607773 3568259 4481205 -1131686 -1824955 5306491 3932519 197992 562715 5108499 3369804 X SENS Research Foundation works to research, develop, and promote comprehensive regenerative medicine solutions for the diseases and disabilities of aging. The research is governed by a strategic agenda to demonstrate the feasibility of rejuvenation biotechnologies, as a natural extension of regenerative medicine as applied to aging, and therefore drive broader involvement. 0 0 1438002 The intramural research program is carried out in the Organization's Mountain View facility by employees of the Organization. The program is comprised of two (2) separate lines of research: Mitochondrial mutations and Immuno-senescence. The Mitochondrial mutations line of research has completed proof of concept and is moving ahead with their work, presenting their findings at conferences internationally. The Immuno project is full-time with a new Team Lead and a sub project run by a Post-Doctoral Fellow. 548709 476089 The extramural research program funds some of the most prestigious institutions around the world. There are currently 5 extramural research projects ongoing. Funding for this program continues to be prioritized for projects that meet our company mission and are currently being unaddressed in our intramural research program. 637246 158297 SRF Education - As part of its mission, the Organization is committed to educating students and the public about rejuvenation biotechnologies. The Organization's student program, SRF Education Academic Initiative, is committed to educating students and the public. SRF Education operates a summer internship program that places twelve (12) undergraduate students at the SRF Research Center and outside institutions. It also continues a program to place nine (9) post-baccalaureate students at various institutions, including four (4) at the SRF Research Center. The Education program continues to grow in size and outreach capacities. 96729 Educational Conferences - In addition to participation in a variety of scientific and public engagements, the Organization organizes its own conferences and events. These include the Undoing Aging Conference in Berlin, Germany. This outreach is intended to inform both the scientific community and the general public about damage repair strategies for improving healthcare. 894918 Other programs - The Organization conducts other programs related to the mission of the organization. 991647 3615604 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 21 0 1 34 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X The Organization 6503361780 110 Pioneer Way J Mountain View CA 94041 Barbara Logan Chairperson 4.00 X X 0 0 0 Kevin Perrott Treasurer 2.00 X X 0 0 0 Bill Liao Secretary 2.00 X X 0 0 0 Kevin Dewalt Director 1.00 X 0 0 0 Michael Boocher Director 1.00 X 0 0 0 Jonathan Cain Director 1.00 X 0 0 0 James O'Neill Director 1.00 X 0 0 0 Frank Schuler Director 1.00 X 0 0 0 Michael Kope President/CEO 40.00 X X 206746 0 6202 Aubrey de Grey Chief Science Officer 40.00 X 81128 0 12024 Matthew O'Connor VP Research 40.00 X 144722 0 11277 Lisa Fabiny VP Operations 40.00 X 139783 0 26843 Gregory Chin Director of Education 40.00 X 124338 0 11575 696717 0 67921 4 0 1 0 0 2589086 261475 2589086 4279 4279 582289 618802 -36513 -36513 -36513 Miscellaneous Income 900099 95803 68203 27600 Publication Sales 900099 3595 3595 99398 2656250 71798 27600 -32234 X 686639 686639 28532 28532 -80785 -80785 577979 408588 57020 112371 1338756 1124398 98523 115835 32770 24879 3974 3917 133492 93096 13181 27215 156049 122708 14813 18528 26970 26687 283 74739 74739 667267 553565 108992 4710 379 364 15 15533 570 14809 154 218043 183086 23050 11907 93664 67188 14752 11724 78093 67865 10228 105664 73004 29581 3079 15429 15429 Equipment and supplies 134341 134183 158 0 Bad debt expense 50000 50000 Small computer equipmen 35413 12976 22314 123 Patentry Expenses 19620 19620 72618 18441 41501 12676 4481205 3615604 533134 332467 4884768 2816650 2141 13958 837621 747666 560642 64873 187024 272777 98 81932 77168 5306491 3932519 197992 496789 0 65926 197992 562715 X 4702154 3052713 406345 317091 5108499 3369804 5306491 3932519 -1824955 86260 0 X X 0 1 X 1 0 X 1429790 2684540 7840321 3531916 2589086 18075653 1429790 2684540 7840321 3531916 2589086 18075653 7913015 10162638 6817 3908 28016 2478 4279 45498 7081 7081 18128232 265482 0.56060 0.56890 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 480711 407297 73414 266955 153345 113610 187024 Lease Incentive 65926 65926 X 2742510 86260 86260 2656250 0 2656250 4481205 0 4481205 0 4481205 Part X, Line 2: The Organization evaluates its uncertain tax positions and will recognize a loss contingency when it is probable that a liability has been incurred as of the date of the financial statements and the amount of the loss can be reasonably estimated. The amount recognized is subject to estimate and management judgment with respect to the likely outcome of each uncertain tax position. The amount that is ultimately sustained for an individual uncertain tax position or for all uncertain tax positions in the aggregate could differ from the amount recognized. As of December 31, 2019, management did not identify any uncertain tax positions. 1 0 0 0 0 0 0 0 0 0 Babraham Hall House, Babraham, Cambridge CB22 3AT, United Kingdom Research grant, Jonathan Clark grant extension 197561 Wire Standing Way, Eaglestone, Milton Keynes MK6 5LD, United Kingdom Research funding CHESS study 119652 Wire Europe Return of research project funds -397998 Wire 3 0 0 0 0 0 0 Part III Accounting Method: 1 Buck Institute for Research on Aging 8001 Redwood Blvd Novato CA 94945 943030609 501c3 219090 Extramural research Yale Office of Sponsored Projects 433 Temple Street New Haven CT 06511 060646973 501c3 180388 Extramural research Albert Einstein College of Medicine 1300 Morris Park Ave The Bronx NY 10461 131624225 501c3 149999 Extramural research Rational Vaccines Inc 21 Erie Street Cambridge MA 02139 473347600 42618 Extramural research Aspen Neuroscience Inc 10835 Rd to the Cure San Diego CA 92121 831312969 41700 Educational grant Health Research Inc 150 Broadway Menands NY 12204 141402155 501c3 33869 Extramural research Sanford-Burnham Medical Research Inst 10901 N Torrey Pines Rd La Jolla CA 92037 510197108 501c3 11000 Educational grant Stanford University 450 Serra Mall Stanford CA 94305 941156365 501c3 8975 Educational grant The Scripps Research Institute 10550 N Torrey Pines Rd La Jolla CA 92037 330435954 501c3 -1000 Return of educational research grant 7 2 Research grants 4 28532 Part I, Line 2: The Organization monitors grants at three month intervals. We require interim research reports every three months, which are submitted with the next payment invoice. At the conclusion of each research contract, we require a comprehensive research report and a financial accounting that details how the grant was spent. X X 0 0 0 0 0 0 0 0 0 Michael Kope President/CEO 206746 0 0 0 0 0 6202 0 0 0 212948 0 0 0 Matthew O'Connor VP Research 144722 0 0 0 0 0 3802 0 7475 0 155999 0 0 0 Lisa Fabiny VP Operations 139783 0 0 0 0 0 4362 0 22481 0 166626 0 0 0 X 900 165872 FMV X Crypto currency 466 95603 FMV 0 0 0 Part I, Column (b): In column b, the Organization is reporting the number of units received that year. Form 990, Part VI, Section B, line 11b The form 990 is reviewed by the President and the Vice President of the Operations and presented to the Board prior to filing. Form 990, Part VI, Section B, line 12c A formal conflict of interest policy has been adopted by the organization. The policy is reviewed and reaffirmed annually. Form 990, Part VI, Section B, line 15 The president's salary was determined through the budget process by the board of directors. The board used comparable data for determining salaries of all key employees. Form 990, Part VI, Section C, line 18 The forms 1023 and 990 are available at the organization's offices upon request. Form 990, Part VI, Section C, line 19 All governing documents, the conflict of interest policy and the financial statements are available at the organization's offices upon request Form 990, Part IX, line 11g Lab Services: Program service expenses 256,867. Management and general expenses 0. Fundraising expenses 0. Total expenses 256,867. Payroll Service Fees: Program service expenses 607. Management and general expenses 26,360. Fundraising expenses 0. Total expenses 26,967. Other Services: Program service expenses 296,091. Management and general expenses 82,632. Fundraising expenses 4,710. Total expenses 383,433. Form 990, Part XII, Line 2c The Organization's audit committee is charged with the responsibility of overseeing the audit and the work of the independent auditors. This process has not changed from prior years.